# Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer

> **NCT00006230** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 51 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** rubitecan

## Key facts

- **NCT ID:** NCT00006230
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-05
- **Primary completion:** 2003-04
- **Final completion:** —
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2012-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006230, "Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00006230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*